Pancreatic ductal adenocarcinoma (PDAC) is characterized by an extensive stromal component that hinders treatment. A new study shows how the genetic identity of pancreatic tumors might influence the physical properties of the associated stroma to promote tumor progression.
desmoplastic reaction to pancreatic tumorigenesis is controversial; there is evidence consistent with both contributory and inhibitory effects of such a reaction on tumorigenesis.
In mouse models of PDAC, long-term inhibition of or genetic deletions that limit the ability of pancreatic epithelial cells to respond to paracrine-acting, tumor-secreted Hedgehog peptides, which enhance the tumor desmoplastic reaction 6 , led to reductions in stromal content and an increase in tumor aggression, whereas Hedgehog pathway activation in PDAC tumors with small-molecule agonists increased stromal fibrosis and reduced epithelial cell proliferation 7, 8 . Furthermore, in another mouse model, the depletion of α-SMA-expressing myofibroblasts resulted in invasive, undifferentiated PDAC tumors with reduced survival 9 . These observations suggest that the stromal component restrains PDAC. In addition, antistromal therapies for PDAC have not demonstrably improved patient survival or therapeutic responses in clinical trials 1 . One possible explanation for the apparent restraining actions of the stromal component is that 'classical' mouse models are not adequate representations of the contribution of the stroma to PDAC. In particular, changes in protein expression might not reflect the influence that ECM protein organization, and the consequent mechanical properties of the tumor microenvironment, have on PDAC growth and progression.
Laklai et al. 2 found in a number of human tumor samples that there were clear associations between poor PDAC differentiation, increased collagen-fiber diameters and increased epithelial phosphorylated regulatory myosin light chain-2 (p-MLC2) relative to moderately and well-differentiated tumors, which is consistent with previously established links of tumor cell actomyosin tension and stromal remodeling to PDAC progression. Furthermore, patients with thickened collagen fibers adjacent to pancreatic lesions, or increased epithelial p-MLC2, had the shortest survival time, which suggests that altered ECM organization contributed to patient mortality. Reduced patient survival was also associated with lower TGF-β signaling, relative to longer-surviving patients, and samples from patients with SMAD4 mutations had abundant collagen fibers, increased stiffness adjacent to pancreatic lesions and elevated p-MLC2. Taken together, these results revealed significant links between TGF-β signaling, ECM organization, tissue stiffness, epithelial cell actin-myosin tension and patient outcomes.
TGF-β signaling proteins are frequently altered in human PDAC, with the cumulative frequency of mutations in genes encoding TGF-β ligand receptors TGFBR1 and TGFBR2, and downstream transcription factors SMAD3 and SMAD4 being >50% (ref. 3) . To determine how the disruption of this pathway might contribute to PDAC, Laklai et al. 2 compared the fibrotic properties of tumors from KC or KPC mice with tumors from mice expressing oncogenic KRAS along with the pancreas-selective deletion of one TGF-β receptor-2 (encoded by Tgfbr2) allele (KTC). Although the expression of myofibroblast markers and the expression of total collagen levels were not different, collagen bundles were thicker in KTC tumors than in both KC and KPC tumors, and they were associated with stiffer tissue. Along with these altered physical properties, KTC cells manifested several molecular responses that are typically induced mechanically, including nuclear accumulation of the YAP transcription factor, activated β1-integrin, phosphorylated active focal adhesion kinase (PTK2, also known as FAK), and p-MLC2. The KTC cells generated more actin-myosin mediated contractile force in vitro than did the KPC and KC cells, which was dependent on the phosphorylation of MLC2 by the Rho kinase-1 (ROCK1) protein kinase. When implanted into immunocompromised mice, KTC tumor cells induced ROCK1-dependent fibrosis, indicating that cell contractility leads to ECM protein remodeling, which in turn sends signals via mechanoresponsive pathways to increase cellular tension (Fig. 1) .
Laklai et al. 2 next sought to identify signaling pathways that are altered by a Tgfbr2 deletion in PDAC. Tumor cells have been previously shown to signal via a cytokine-induced, G-protein-coupled Pancreatic cancer is a leading cause of cancerrelated deaths, with poor survival rates and little improvement in patient outcomes, despite considerable effort directed at optimizing therapies 1 . To improve therapeutic responses and increase survival, researchers must identify the factors that make pancreatic cancer so deadly and so difficult to treat. In this issue of Nature Medicine, Laklai et al. 2 reveal how mechanical properties of the pancreatic cancer microenvironment promote tumor aggressiveness.
Numerous studies have examined genomic alterations in pancreatic cancer 3 . These have revealed the prevalence of KRAS mutations that constitutively activate the protein and consequently increase mitogen-activated protein kinase pathway signaling; TP53 tumor suppressor loss of function mutations; and loss of function mutations in mothers against DPP homolog 4 (SMAD4) that impair transforming growth factor-β (TGF-β)-induced changes in gene expression, all within a landscape of additional genetic variation. The most common pancreatic cancer is PDAC, which develops from cells that line the exocrine ducts that conduct digestive enzymes from acinar cells for delivery to the duodenum. Genetically engineered mouse models of PDAC that closely recapitulate human PDAC development and progression have been established through the use of oncogenic Kras that is selectively expressed in the pancreas, either alone (KC) or in combination with mutated Trp53 (KPC) 4, 5 .
PDAC is characterized by dense fibrous stroma composed of numerous cell types, including macrophages and α-smooth muscle actin (α-SMA)-positive myofibroblasts, and the deposition of extracellular matrix (ECM) material such as collagen 1 and hyaluronic acid. In fact, transformed pancreatic epithelial cells are a minor constituent of PDAC tumors, with stromal components comprising the bulk of the tumor mass. The contribution of this Regulation of pancreatic cancer aggressiveness by stromal stiffening acts via mechanoresponsive pathways in a feedforward loop to amplify cellular responses that promote PDAC growth and progression (Fig. 1) . The human relevance of these findings is supported by data from clinical samples indicating that patients with PDAC who experience shorter survival times have elevated p-STAT3, p-MLC2, nuclear YAP levels and increased collagen bundling, which were also observed in PDAC patients with PDAC who have SMAD4 mutations.
This study has several important implications. First, the comparison of total levels of collagen protein between tumors overlooks the importance of collagen-fiber remodeling (such as bundling and cross-linking) in altering the stromal physical properties that may have substantial roles in PDAC. As a result, methods that detect collagen organization, such as secondharmonic-generation microscopy, complement the information acquired from collagen staining alone. Second, certain PDAC genotypes, particularly those with TGF-β-signaling alterations, generate actomyosin contractile force to remodel ECM proteins and increase proximal stromal stiffness. This observation suggests that targeting both tumor and stromal cells to reduce the tumor-promoting influence of the microenvironment would probably be more efficacious than stromal cell targeting alone. The interactions between PDAC genotypes and tumor mechanical properties, highlighted by Laklai et al. 2 , reinforce the importance of incorporating genetic context into future stromal-targeted-therapy development.
adhesion signaling in the pancreas. The inclusion of active β1-integrin in KC mice was sufficient to recapitulate KTC phenotypes, including an increase in fibrosis, stromal stiffening, elevations in p-STAT3, p-FAK and p-MLC2 and progression to PDAC. The effect of active β1-integrin was reversed by knockdown or inhibition of FAK, which indicates that focal adhesion signaling was the key mediator of the effects of active β1-integrin.
Similarly, KC mice expressing one allele of constitutively active STAT3 (ref. 12) (KC/ STAT3C) were generated, which resulted in elevated p-FAK and p-MLC2, increased fibrosis, stromal stiffening and reduced survival, relative to control KC mice. In KTC mice lacking both alleles of Tgfbr2, combined with pancreas-selective deletion of both copies of Stat3, there was complete reversal of the KTC phenotype and increased survival.
Taken together, these findings indicate that in PDAC, reduced TGF-β signaling enables cell contractility, which leads to ECM remodeling, increased microenvironmental stiffness and elevated JAK-STAT signaling. This signaling receptor (GPCR)-JAK-STAT pathway to induce actomyosin contractility, whereas ROCKmediated contractility in tumor cells increases JAK-STAT signaling by inducing cytokine expression and secretion 10 . KTC tumors had elevated levels of active phosphorylated STAT3 (p-STAT3) and improved collagen-contracting ability relative to KC or KPC tumors, indicating activation of the JAK-STAT pathway. KTC cellconditioned medium also increased KC tumor cell p-STAT3 levels and enhanced collagen contraction in vitro. In addition, JAK-inhibitor treatment reduced collagen contraction by KTC cells, or by KC cells treated with KTC-conditioned medium relative to untreated cells. These results implicate an elevation of GPCR-JAK-STAT signaling in the increase in actomyosin tension and matrix remodeling by PDAC cells with impaired TGF-β signaling.
To determine whether mechanoresponsive signaling was sufficient to promote PDAC progression, the authors generated KC mice with pancreas-selective expression of V737N β1-integrin (KC/β1-V737N) 11 to drive ligandindependent integrin clustering and focal 
